ArriVent BioPharma, Inc.

NasdaqGM:AVBP Stok Raporu

Piyasa değeri: US$1.0b

ArriVent BioPharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

ArriVent BioPharma has a total shareholder equity of $296.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $308.9M and $12.2M respectively.

Anahtar bilgiler

0%

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranın/a
NakitUS$298.67m
EşitlikUS$296.66m
Toplam yükümlülüklerUS$12.20m
Toplam varlıklarUS$308.86m

Son finansal sağlık güncellemeleri

Recent updates

We Think ArriVent BioPharma (NASDAQ:AVBP) Can Afford To Drive Business Growth

Sep 24
We Think ArriVent BioPharma (NASDAQ:AVBP) Can Afford To Drive Business Growth

ArriVent BioPharma: Bringing A Novel Cancer Drug From China

Sep 17

ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment

Jan 29

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: AVBP's short term assets ($308.5M) exceed its short term liabilities ($12.1M).

Uzun Vadeli Yükümlülükler: AVBP's short term assets ($308.5M) exceed its long term liabilities ($98.0K).


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: AVBP is debt free.

Borcun Azaltılması: AVBP had no debt 5 years ago.


Bilanço


Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: AVBP has sufficient cash runway for more than 3 years based on its current free cash flow.

Tahmini Nakit Akışı: Insufficient data to determine if AVBP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Sağlıklı şirketleri keşfedin